European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
02 Jun

European equities traded in the US as American depositary receipts kicked off the trading week higher late Monday morning, rising 0.50% to 1,465.31 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm BioNTech (BNTX) and pharmaceutical company Ascendis Pharma (ASND), which surged 18% and 6.9% respectively. They were followed by biotech firm Evaxion (EVAX) and furniture maker Natuzzi (NTZ), which increased 4.9% and 3.8% respectively.

The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and internet browser company Opera (OPRA), which dropped 3.4% and 2.3% respectively. They were followed by electronics conglomerate Royal Philips (PHG) and Unilever (UL), which lost 1.6% and 0.6% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Mereo BioPharma Group (MREO) and Amarin (AMRN), which rose 4% and 3% respectively. They were followed by biopharmaceutical companies Verona Pharma (VRNA) and Bicycle Therapeutics (BCYC), which were up 2.6% and 2.3% respectively.

The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and communications group WPP (WPP), which fell 2.7% and 2.4% respectively. They were followed by software firm Endava (DAVA) and biopharmaceutical company Adaptimmune Therapeutics, which were down (ADAP) 2.1% and 1.3% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10